🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

181 results for “anti-” Clear

  1. TRU-016 (anti-CD37 protein therapeutic)

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia (CLL)

    phase 1 small molecule completed

    1 trial

  2. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    NovoThirteen

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  3. Trial of the novel peroral anti-tumor treatment in patients with solid tumors

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

    phase 1 other active

    1 trial

  4. ZF874

    Centessa Pharmaceuticals plc

    Alpha1 Anti-Trypsin Deficiency

    phase 1 small molecule terminated

    1 trial

  5. anti CD19 CAR NK cells

    The First People's Hospital of Lianyungang

    Antisynthetase Syndrome

    phase 1 mab active

    1 trial

  6. anti-BCMA/CD70-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    CAR T Cell Therapy

    phase 1 mab active

    1 trial

  7. anti-CD123 CAR-T treatment

    Nanjing Legend Biotech Co.

    Acute Leukemia

    phase 1 small molecule terminated

    1 trial

  8. anti-CD19 CAR NK

    Chongqing Precision Biotech Co., Ltd

    NHL

    phase 1 mab active

    1 trial

  9. anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    B-cell Adult Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  10. anti-CD19 allo-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed Adult ALL

    phase 1 mab active

    1 trial

  11. anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells

    The First People's Hospital of Lianyungang

    Relapsed/refractory Lymphoma

    phase 1 mab active

    1 trial

  12. anti-CD19-CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Systemic Lupus Erythematosus

    phase 1 mab active

    1 trial

  13. anti-EGFR monoclonal antibody

    Dragonboat Biopharmaceutical Company Limited

    Healthy Volunteers

    phase 1 small molecule active

    1 trial

  14. anti-thymocyte globulin

    Ultragenyx UK Limited

    Multiple Sclerosis

    phase 1 small molecule completed

    1 trial

  15. anti-thymocyte globulin

    Ultragenyx UK Limited

    Systemic Lupus Erythematosus

    phase 1 small molecule active

    1 trial

  16. Anti-Arrhythmics

    Rhythm Pharmaceuticals Netherlands B.V.

    Arrhythmia, Cardiac

    approved small molecule terminated

    1 trial

  17. Anti-Platelet Drugs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Unstable Angina

    approved small molecule active

    3 trials

  18. Anti-hypertensive therapy

    Arrowhead Pharmaceuticals Ireland Limited

    Hypertension

    approved small molecule completed

    1 trial

  19. Anti-peristaltic ileosigmoid anastomosis

    The First People's Hospital of Lianyungang

    Constipation

    approved other completed

    1 trial

  20. Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis.

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Diseases

    small molecule active

    1 trial

  21. Anti-HER2 CAR-T cells

    The First People's Hospital of Lianyungang

    HER2-positive Advanced Malignant Solid Tumors

    mab active

    1 trial

  22. Anti-PD1

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    small molecule completed

    1 trial

  23. Anti-infective therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchiectasis Adult

    small molecule active

    1 trial

  24. Peak value anti-Xa

    The First People's Hospital of Lianyungang

    Venous Thromboembolism

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources